Skip to main content

Clinical Trials Using Mycophenolate Mofetil

Review the clinical trials studying mycophenolate mofetil on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 50

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Status: Active
Location: 21 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 20 locations
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Location: 4 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Status: Active
Location: 5 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
Mycophenolate Mofetil in Combination with Standard of Care for the Treatment of Glioblastoma
Status: Active
Location: 3 locations
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Status: Active
Location: 2 locations
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Total Marrow and Lymphoid Irradiation as Conditioning Regimen before Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome or Acute Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 3 locations
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients with Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Peritransplant Ruxolitinib for Patients with Primary and Secondary Myelofibrosis
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington